MaxCyte Investor Presentation Deck

● VLX™ ecopert + 9. New Run QC Run Q Rouns M MaxCyte® O Maxdyte VLX Platform Overview Transfect up to 200 billion cells in a fully closed, single-use system in less than 30 minutes Achieve reproducible results, superior transfection efficiency, cell viability and protein expression, even with difficult-to-transfect cell lines Bench-scale, modular equipment with automated flow design, intuitive integrated software and user-friendly open architecture Proprietary Flow Electroporation™ Technology CGMP-compliant, closed, ISO-certified and CE-marked 18 Biotherapeutic Development: Monoclonal Antibodies, Recombinant Proteins and Vaccines Traditional Approach The process begins with transiently expressing product using transfection early on in Discovery phase followed by establishing a stable cell line process (industry standard ~6+ months) in preclinical development and beyond ● Stable cell line development process is lengthy, cumbersome, complex, and costly, and significantly contributes to time to IND filing VLX-Enabled Approach Expedites the production of the required amount of product (multi- gram quantify) to conduct in-vivo and in-vitro studies for IND filing in only ~4-6 weeks This concept introduces a new "speed to product selection" strategy, enabling investment in stable cell line development only for promising/successful drug candidates © 2023 MaxCyte, Inc. All Rights Reserved

View entire presentation